Not signed in (Sign In)
Hallo Gast!
Willst du auch dazu beitragen? Wenn du schon einen Account hast, dann log dich jetzt ein oder erstell jetzt einfach einen Account
    • CommentAuthorFreekaze
    • CommentTimeJul 5th 2024
    Ponatinib hydrochloride (HCl) API, a tyrosine kinase inhibitor, has emerged as a powerful tool in treating certain types of leukemia. However, its journey since FDA approval has been marked by both promise and controversy. While clinical trials demonstrated its efficacy, real-world evidence (RWE) is crucial for understanding its effectiveness and safety in everyday clinical practice.